Procurement Summary
Country: United Kingdom
Summary: Pace Interim Impact Report
Deadline: 09 Jan 2026
Posting Date: 09 Dec 2025
Other Information
Notice Type: Tender
TOT Ref.No.: 131701616
Document Ref. No.:
Financier: Self Financed
Purchaser Ownership: Public
Tender Value: Refer Document
Purchaser's Detail
Name: Login to see tender_details
Address: Login to see tender_details
Email: Login to see tender_details
Login to see detailsTender Details
PACE (Pathways to Antimicrobial Clinical Efficacy) is a £30 million initiative supporting and funding early-stage innovation in medicines and diagnostics, aimed at tackling AMR. It was established in September 2023 and is a collaboration between Innovate UK (IUK), LifeArc, and Medicines Discovery Catapult (MDC) - three leaders in the UK's health innovation and research community. PACE brings together the funding, resources, and partnerships to help innovators progress their early-stage antimicrobial drug and diagnostics projects with greater speed, support and confidence - giving the best AMR innovations the greatest chance of success. PACE will create a path to value through 3 strategic goals which will be underpinned by effective programme management and delivery: Grow a pipeline of high-quality antimicrobial drugs and associated diagnostics aligned with unmet needs and route to patient impact. Provide innovative researchers in Academia and SMEs located globally the funding, advice and support they need to build de-risked and investment ready assets Convene collaboration network(s) to identify barriers to innovation, advance programmes and drive new collaborative R&D. It is a requirement of MDC's grant funding agreement with Innovate UK and LifeArc that the outcomes and long-term impacts of PACE activities are assessed at key time points throughout the programme's timeline. The PACE programme is funded for an initial term of five years and as of April 2026 will reach its m...
Documents
Tender Notice